Atrial Fibrillation Pipeline Insight 2025: 15+ Pipeline Drugs, Gene Therapies, and Digital Rhythm Management Drive Innovation | DelveInsight

DelveInsight's "Atrial Fibrillation - Pipeline Insight, 2025" examines more than 15+ therapies in development for atrial fibrillation (AF), the most common sustained cardiac arrhythmia associated with stroke, heart failure, and reduced quality of life. While antiarrhythmic drugs, anticoagulants, and catheter ablation remain the cornerstones of care, the high relapse rates and long-term risks highlight significant unmet needs in the atrial fibrillation treatment market.

The atrial fibrillation pipeline is expanding beyond traditional pharmacology, with novel oral anticoagulants, atrial-selective ion channel blockers, and gene therapies aiming to target disease mechanisms at the molecular level. Regenerative strategies are being explored to repair atrial tissue, while digital health tools and AI-enabled rhythm monitoring are advancing precision management. In parallel, minimally invasive ablation devices and pulsed-field ablation technologies are reshaping procedural outcomes, offering safer and more durable rhythm control options in the atrial fibrillation treatment landscape.

With atrial fibrillation clinical trials progressing across biologics, small molecules, interventional devices, and digital solutions, the future outlook is shifting toward integrated care models. As emerging drugs and technologies converge, the atrial fibrillation market is expected to transform into a multi-modal ecosystem where pharmacological innovation, device-based therapy, and intelligent monitoring work together to reduce burden, prevent complications, and improve long-term outcomes.

Interested in learning more about the current treatment landscape and the key drivers shaping the Atrial Fibrillation pipeline? Click here: https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Atrial Fibrillation Pipeline Report
• DelveInsight's Atrial Fibrillation pipeline analysis depicts a strong space with 15+ active players working to develop 12+ pipeline drugs for Atrial Fibrillation treatment.
• The leading Atrial Fibrillation companies include Bayer AG, HUYA Bioscience, InCarda Therapeutics, Milestone Pharmaceuticals, Verseon, Thryv Therapeutics, Vivasc Therapeutics, and others, who are evaluating their lead assets to improve the Atrial Fibrillation treatment landscape.
• Key Atrial Fibrillation pipeline therapies in various stages of development include Asundexian, HBI-3000, Inrhythm, Etripamil, VE 1902, Research programme, CTP-Amio, and others.
• In Sept 2025, Pulse Biosciences received FDA approval for its Investigational Device Exemption (IDE) to start the NANOCLAMP AF study, testing its Nanosecond Pulsed Field Ablation (nsPFA) technology for treating atrial fibrillation.
• In September 2025, Kardium Inc. received FDA pre-market approval (PMA) for its Globe Pulsed Field System and 510(k) clearance for the Globe Introducer sheath and mapping software. The integrated platform supports high-density cardiac mapping and single-shot pulmonary vein isolation (PVI) for atrial fibrillation treatment using a single catheter.
• In July 2025, Boston Scientific received FDA approval to expand the labeling of its FARAPULSE Pulsed Field Ablation System for treating drug-refractory, symptomatic persistent atrial fibrillation (AF), a heart arrhythmia lasting at least seven days. AF affects around 59 million people worldwide and increases stroke risk. The system uses pulsed field energy to ablate heart tissue and now includes both FARAWAVE and FARAWAVE NAV catheters for persistent AF treatment.
• In May 2025, CoreMap announced FDA approval of its Investigational Device Exemption (IDE) to expand the INvENI clinical study in the U.S. The study evaluates the safety and effectiveness of the CoreMap Endocardial Electrophysiology Mapping System for patients with persistent and long-standing persistent Atrial Fibrillation.
• In April 2025, Medtronic announced positive clinical outcomes from two studies on atrial fibrillation (AFib) patients treated with the AfferaTM family of technologies. This includes the next-generation Sphere-360 single-shot pulsed field ablation (PFA) catheter and the Sphere-9TM combination mapping and dual-energy focal PFA catheter. The data were presented at the Heart Rhythm Society 2025 Annual Meeting in San Diego, with the Sphere-360 study also published in the Heart Rhythm Journal.

Request a sample and discover the recent breakthroughs happening in the Atrial Fibrillation pipeline landscape at https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Atrial Fibrillation Overview
Atrial fibrillation (AFib) is the most common type of irregular heart rhythm, characterized by rapid and disorganized electrical signals in the atria, the heart's upper chambers. This leads to an irregular and often rapid heartbeat, which can reduce the heart's efficiency in pumping blood. AFib can cause symptoms such as palpitations, shortness of breath, fatigue, and dizziness. It also increases the risk of stroke, heart failure, and other cardiovascular complications due to the formation of blood clots in the atria.

The causes of atrial fibrillation are diverse and include high blood pressure, heart disease, thyroid disorders, and excessive alcohol consumption, among others. Management of AFib involves controlling the heart rate, restoring normal rhythm when possible, and reducing stroke risk through anticoagulation therapy. Treatment options range from lifestyle changes and medications to invasive procedures like catheter ablation, depending on the severity and underlying cause of the condition.

Find out more about Atrial Fibrillation medication at https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Atrial Fibrillation Treatment Analysis: Drug Profile
Etripamil: Milestone Pharmaceuticals Inc.
Etripamil is an investigational, fast-acting L-type calcium channel blocker administered via nasal spray. It is being developed as an on-demand, self-administered treatment for paroxysmal supraventricular tachycardia (PSVT). As the lead candidate from Milestone Pharmaceuticals, Etripamil aims to provide rapid symptom relief outside clinical settings, potentially revolutionizing the management of PSVT and atrial fibrillation with rapid ventricular rate (AFib-RVR). The drug is currently in Phase III clinical trials for AFib-RVR.

HBI-3000: HUYA Bioscience
HBI-3000 is a multi-ion channel blocker developed by HUYABIO International, targeting several ion channels, including INa-Peak, INa-Late, ICa, L, and IKr, and is intended for converting recent-onset atrial fibrillation to normal rhythm. Preclinical and clinical data suggest HBI-3000 has the potential to restore sinus rhythm with a low risk of proarrhythmia. Initial Phase I data for the intravenous formulation were presented at the 2019 American Heart Association annual meeting. The drug is currently in Phase II development for treating atrial fibrillation.

Learn more about the novel and emerging Atrial Fibrillation pipeline therapies at https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Atrial Fibrillation Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Atrial Fibrillation Pipeline Report
• Coverage: Global
• Key Atrial Fibrillation Companies: Bayer AG, HUYA Bioscience, InCarda Therapeutics, Milestone Pharmaceuticals, Verseon, Thryv Therapeutics, Vivasc Therapeutics, and others.
• Key Atrial Fibrillation Pipeline Therapies: Asundexian, HBI-3000, Inrhythm, Etripamil, VE 1902, Research programme, CTP-Amio, and others.

To dive deep into rich insights for drugs used for Atrial Fibrillation treatment, visit: https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Atrial Fibrillation Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Atrial Fibrillation Pipeline Therapeutics
6. Atrial Fibrillation Pipeline: Late-Stage Products (Phase III)
7. Atrial Fibrillation Pipeline: Mid-Stage Products (Phase II)
8. Atrial Fibrillation Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.